Literature DB >> 24496789

[Surgical options in cancer of unknown primary (CUP)].

T Schmidt1, A Ulrich.   

Abstract

BACKGROUND: Cancer of unknown primary site (CUP) comprises a relatively frequently occurring group of heterogeneous malignant tumors in the clinical routine, which currently has an abysmal prognosis for affected patients. Based on the improved diagnostic tools it is now possible to identify subgroups of patients with different clinical prognoses. New therapies adapted to these identified subgroups are becoming increasingly more relevant. AIM: This review aims to evaluate the role of surgery and different surgical options in the therapy of patients with CUP.
RESULTS: For the treatment of patients with CUP it is important to identify subgroups of patients with a better prognosis. Surgical resection of CUP metastasis is a therapy option leading to a prolonged survival in (1) women with papillary peritoneal adenocarcinomatosis, (2) women with axillary lymph node metastasis of adenocarcinoma, (3) patients with cervical lymph node metastasis of squamous cell carcinoma, (4) patients with inguinal lymph node metastasis, (5) patients with poorly differentiated carcinomas with midline distribution (e.g. extragonadal germ cell syndrome) and (6) patients with small resectable tumors.
CONCLUSION: Surgery is an important therapy option in different subgroups of patients with CUP. Together with multimodal therapy, adjusted according to the identified most likely origin of the primary tumor, it is possible to prolong patient survival.

Entities:  

Mesh:

Year:  2014        PMID: 24496789     DOI: 10.1007/s00117-013-2549-7

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  33 in total

1.  Role of postchemotherapy adjunctive surgery in the management of patients with nonseminoma arising from the mediastinum.

Authors:  J Vuky; M Bains; J Bacik; G Higgins; D F Bajorin; M Mazumdar; G J Bosl; R J Motzer
Journal:  J Clin Oncol       Date:  2001-02-01       Impact factor: 44.544

2.  Survival in cancer of unknown primary site: population-based analysis by site and histology.

Authors:  K Hemminki; M Bevier; A Hemminki; J Sundquist
Journal:  Ann Oncol       Date:  2011-11-24       Impact factor: 32.976

3.  Chemotherapy for patients with two favourable subsets of unknown primary carcinoma: active, but how effective?

Authors:  George Pentheroudakis; Evangelos Briasoulis; Vassilis Karavassilis; George Fountzilas; Nikolaos Xeros; George Samelis; Epaminondas Samantas; Nicholas Pavlidis
Journal:  Acta Oncol       Date:  2005       Impact factor: 4.089

Review 4.  Cancer of unknown primary site.

Authors:  Nicholas Pavlidis; George Pentheroudakis
Journal:  Lancet       Date:  2012-03-12       Impact factor: 79.321

Review 5.  Colorectal cancer.

Authors:  David Cunningham; Wendy Atkin; Heinz-Josef Lenz; Henry T Lynch; Bruce Minsky; Bernard Nordlinger; Naureen Starling
Journal:  Lancet       Date:  2010-03-20       Impact factor: 79.321

6.  The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer.

Authors:  Oliver Zivanovic; Eric L Eisenhauer; Qin Zhou; Alexia Iasonos; Paul Sabbatini; Yukio Sonoda; Nadeem R Abu-Rustum; Richard R Barakat; Dennis S Chi
Journal:  Gynecol Oncol       Date:  2007-11-13       Impact factor: 5.482

Review 7.  Cancer of unknown primary site: missing primary or missing biology?

Authors:  George Pentheroudakis; Evangelos Briasoulis; Nicholas Pavlidis
Journal:  Oncologist       Date:  2007-04

8.  Experience with platinum-paclitaxel chemotherapy in the initial management of papillary serous carcinoma of the peritoneum.

Authors:  A W Kennedy; M Markman; K D Webster; B Kulp; G Peterson; L A Rybicki; J L Belinson
Journal:  Gynecol Oncol       Date:  1998-11       Impact factor: 5.482

Review 9.  Diagnostic and therapeutic management of cancer of an unknown primary.

Authors:  N Pavlidis; E Briasoulis; J Hainsworth; F A Greco
Journal:  Eur J Cancer       Date:  2003-09       Impact factor: 9.162

10.  Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi-institutional study.

Authors:  M Deraco; S Virzì; D R Iusco; F Puccio; A Macrì; C Famulari; M Solazzo; S Bonomi; A Grassi; D Baratti; S Kusamura
Journal:  BJOG       Date:  2012-06       Impact factor: 6.531

View more
  1 in total

Review 1.  CUP Syndrome-Metastatic Malignancy with Unknown Primary Tumor.

Authors:  Gregor Zaun; Martin Schuler; Ken Herrmann; Andrea Tannapfel
Journal:  Dtsch Arztebl Int       Date:  2018-03-09       Impact factor: 5.594

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.